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Abstract
Copy number variation (CNV) at chromosomal region 15q11.2 is linked to increased risk of neurodevelopmental
disorders including autism and schizophrenia. A significant gene at this locus is cytoplasmic fragile X mental
retardation protein (FMRP) interacting protein 1 (CYFIP1). CYFIP1 protein interacts with FMRP, whose monogenic
absence causes fragile X syndrome (FXS). Fmrp knock-out has been shown to reduce tonic GABAergic inhibition
by interacting with the -subunit of the GABAA receptor (GABAAR). Using in situ hybridization (ISH), qPCR,
Western blotting techniques, and patch clamp electrophysiology in brain slices from a Cyfip1 haploinsufficient
mouse, we examined -subunit mediated tonic inhibition in the dentate gyrus (DG). In wild-type (WT) mice, DG
granule cells (DGGCs) responded to the -subunit-selective agonist THIP with significantly increased tonic
currents. In heterozygous mice, no significant difference was observed in THIP-evoked currents in DGGCs.
Phasic GABAergic inhibition in DGGC was also unaltered with no difference in properties of spontaneous IPSCs
(sIPSCs). Additionally, we demonstrate that DG granule cell layer (GCL) parvalbumin-positive interneurons
(PV-INs) have functional -subunit-mediated tonic GABAergic currents which, unlike DGGC, are also modulated
by the 1-selective drug zolpidem. Similar to DGGC, both IPSCs and THIP-evoked currents in PV
-INs were not
different between Cyfip1 heterozygous and WT mice. Supporting our electrophysiological data, we found no
significant change in hippocampal -subunit mRNA expression or protein level and no change in 1/4-subunit
mRNA expression. Thus, Cyfip1 haploinsufficiency, mimicking human 15q11.2 microdeletion syndrome, does not
alter hippocampal phasic or tonic GABAergic inhibition, substantially differing from the Fmrp knock-out mouse
model.
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Significance Statement
CYFIP1 is a candidate risk gene for neurodevelopmental and neuropsychiatric disorders. CYFIP1 protein
interacts with FMRP whose loss downregulates tonic GABAergic inhibition via interaction with the -subunit
of the GABAA receptor (GABAAR). Here, however, we report that reduced Cyfip1 dosage in mice does not
alter tonic GABAergic inhibition in granule cells and parvalbumin-positive interneurons (PV-INs) of the
dentate gyrus (DG), a region rich in -subunit expression. Despite these negative findings, our data does
demonstrate that PV-INs of the DG granule cell layer (GCL) are functionally regulated by tonic GABAergic
inhibition, and in contrast to granule cells, this involves receptors incorporating both - and 1-subunits.
Thus, GCL excitatory neurons and PV-INs may be differentially modulated by subunit-selective GABA
receptor targeting drugs.
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Introduction
Cytoplasmic fragile X mental retardation protein (FMRP)
interacting protein 1 (CYFIP1) is a gene found in the
15q11.2 locus of the human genome (Chai et al., 2003).
Copy number variations (CNVs) at this region, including
both microdeletions and microduplications, span CYFIP1
and three other genes (NIPA1, NIPA2, TUBGCP5) and
have been strongly linked by genomic studies to in-
creased risk of developing neuropsychiatric and neurode-
velopmental disorders including autism spectrum
disorder and schizophrenia (Stefansson et al., 2008; Burn-
side et al., 2011; Kirov et al., 2012). CYFIP1 has a number
of known functions and the protein it encodes (CYFIP1)
interacts with several key signaling complexes. For exam-
ple, CYFIP1 is involved in the maturation and mainte-
nance of dendritic complexity and dendritic spines by
suppressing the WAVE regulatory complex and regulating
actin cytoskeletal dynamics (De Rubeis et al., 2013;
Pathania et al., 2014). Rodent models of Cyfip1 haploin-
sufficiency, broadly modeling reduced gene dosage of
Cyfip1 in 15q11.2 CNV carriers, reveal behavioral deficits
in the form of altered extinction in inhibitory avoidance,
although wider effects on anxiety and learning were not
observed (Bozdagi et al., 2012).
As indicated by its name, CYFIP1 is an important func-
tional partner of the RNA-binding protein FMRP (Schenck
et al., 2001; Napoli et al., 2008), which regulates dendritic
targeting of mRNAs (Bassell and Warren, 2008), influ-
ences mRNA stability (De Rubeis and Bagni, 2010) and
represses protein translation of 800 neuronal mRNA
“FMRP targets” (Darnell et al., 2001; Hou et al., 2006). The
transcriptional silencing of the FMRP gene FMR1 causes
fragile X syndrome (FXS), which is characterized by a
range of physical, behavioral and cognitive deficits (Gar-
ber et al., 2008) and is the leading monogenic cause of
autism and intellectual disability (Santoro et al., 2012).
In comparison to CYFIP1, the molecular pathways dis-
rupted by FMRP loss have been more extensively char-
acterized. One significant effect of FMRP loss is
disruption of GABAergic signaling across brain regions
including the hippocampus, cortex, and amygdala
(Paluszkiewicz et al., 2011; Braat et al., 2015). FMRP is
expressed in GABAergic interneurons throughout devel-
opment suggesting an important role in interneuron mat-
uration and function (Feng et al., 1997) and a subset of
GABAergic signaling mRNAs appear to be under the reg-
ulation of FMRP (El Idrissi et al., 2005; Darnell et al., 2011).
Fmr1 KO animal studies have revealed that Fmrp loss
produces significant pre- and postsynaptic effects on
GABAergic signaling. Changes in the level of the GABA
synthesizing enzyme glutamatic acid decarboxylase
(GAD65/67), the GABA transporter 1 (GAT-1) and en-
zymes responsible for GABA breakdown (GABA-T and
SSADH) have all been associated with loss of FMRP
(Martin and Huntsman, 2014). Postsynaptically, de-
creased mRNA expression and/or protein levels for at
least eight GABAA receptor (GABAAR) subunits (1, 3, 4,
1, 2, 1, 2, and ) have been described in amygdala,
cortex, and hippocampus (Braat et al., 2015; Sabanov
et al., 2017; Zhang et al., 2017).
In particular, deficits in tonic GABAergic inhibition have
been implicated. FMRP has been shown to bind to the
GABAAR -subunit (Miyashiro et al., 2003; Dictenberg
et al., 2008) and Fmrp knock-out reduces -subunit
mRNA and protein expression in the amygdala, cerebel-
lum, cortex, and dentate gyrus (DG) of a mouse model of
FXS (D’Hulst et al., 2006; Curia et al., 2009; Braat et al.,
2015; Zhang et al., 2017). Moreover, the GABAAR
-subunit-selective agonist THIP and the neurosteroid
ganaxolone ameliorate symptoms in a mouse model of
FXS (Olmos-Serrano et al., 2011; Braat et al., 2015). Im-
portantly, the -subunit is exclusively found in extrasyn-
aptic GABAARs (eGABAARs) and mediates tonic inhibition
across brain regions, although in the hippocampus it is
almost exclusively expressed in the DG (Pirker et al.,
2000; Zheng et al., 2009; Milenkovic et al., 2013). Thus,
the current view is that disrupted tonic GABAergic inhibi-
tion may be a major contributing in FXS and that modu-
lation of GABAergic signaling is a potential route for
therapeutic intervention in this disorder (Braat et al.,
2015).
Therefore, due to the association of CYFIP1 with neu-
ropsychiatric disorders, its known interaction with FMRP
and the effects of FMRP on GABA signaling, we have
used a Cyfip1 haploinsufficient mouse to explore the
effects of Cyfip1 on GABAergic inhibition. We find that,
unlike Fmrp loss, Cyfip1 haploinsufficiency does not re-
duce GABAAR -subunit expression in the hippocampus.
Electrophysiological experiments show that neither pha-
sic IPSCs nor tonic GABAergic inhibition is changed in DG
granule cells (DGGCs) or granule cell layer (GCL)
parvalbumin-positive interneurons (PV-INs). Thus, in
mouse hippocampus, haploinsufficiency of Cyfip1 does
not disrupt GABAergic signaling in a similar manner to
Fmrp knock-out. Nonetheless, our findings reveal that
GCL PV-INs do, as previously suggested (Milenkovic
et al., 2013), express functional eGABAARs containing
-subunits that contribute to tonic inhibition in these cells.
Unlike DGGC (Nusser and Mody, 2002), a fraction of the
tonic current in GCL PV-INs is modulated by the 1-
selective ligand zolpidem suggesting these cells may ex-
press 1-subunit-containing eGABAARs.
Received September 18, 2018; accepted May 31, 2019; First published June
17, 2019.
The authors declare no competing financial interests.
Author contributions: S.T. and A.C.E. designed research; S.T. and A.C.E.
performed research; S.T., W.M.C., and A.C.E. analyzed data; S.T., J.H., and
A.C.E. wrote the paper.
This work was supported by a Wellcome Trust Strategic Award (DEFINE).
A.C.E. was supported by a Jane Hodge Foundation Neuroscience Fellowship,
and S.T. is supported by a Neuroscience and Mental Health Research Institute
Fellowship.
Acknowledgments: We thank Professor Frank Sengpiel and Dr. Adam Ran-
son for supplying PV-cre and tdTomato mice.
Correspondence should be addressed to Adam C. Errington at
erringtonac@cardiff.ac.uk.
https://doi.org/10.1523/ENEURO.0364-18.2019
Copyright © 2019 Trent et al.
This is an open-access article distributed under the terms of the Creative
Commons Attribution 4.0 International license, which permits unrestricted use,
distribution and reproduction in any medium provided that the original work is
properly attributed.
Negative Results 2 of 20
May/June 2019, 6(3) ENEURO.0364-18.2019 eNeuro.org
Materials and Methods
Animals
Experiments involving recordings from DGGCs were
performed on Cyfip1 heterozygous (Cyfip1/–) and wild-
type (WT) mice. The Cyfip1 mouse line (Allele:
Cyfip1tm2a(EUCOMM)Wtsi) was generated using the
“knockout-first” strategy by the Wellcome Trust Sanger
Institute as part of the International Knockout Mouse
Consortium (IKMC) on the C57BL/6N Taconic back-
ground. We obtained pairs of breeding mice (B6NTac;
B6N-Atm1Brd Cyfip1tm2a(EUCOMM)Wtsi/WtsiH) from the
EMMA mouse repository (Infrafrontier Mouse Disease
Models, RRID: IMSR_EM:06868). Experimental animals
were generated by crossing male Cyfip1/– mice with WT
female C57BL/6J mice (RRID: IMSR_JAX:000664), gener-
ating hybrid C57BL/6J/6N Cyfip1/– and WT littermates.
Animals were genotyped following the procedure recom-
mended by the Sanger Institute. For experiments involv-
ing recordings from PV-INs in the DG GCL, we crossed
a PV-Cre knock-in mouse (B6;129P2-Pvalbtm1(cre)Arbr/J,
RRID: IMSR_JAX:008069) with a Cre-dependent tdTo-
mato reporter mouse (B6.Cg-Gt(ROSA)26Sortm14(CAG-td-
Tomato)Hze/J, RRID: IMSR_JAX:007914) to drive expression
of the red fluorescent protein tdTomato in PV cells.
These animals were then subsequently crossed with Cy-
fip1/– mice to produce PVTdCyfip1WT//– mice. Electro-
physiological experiments and protein and mRNA
expression experiments were performed on adolescent
(five- to seven-week-old) or adult (3.5- to six-month-old)
mice. All protein and mRNA expression work was con-
ducted on behaviorally naive, adult male 6J/6N hybrid
mice and further molecular work was performed on be-
haviorally naive adolescent male 6J/6N mice. All animal
procedures were performed in accordance with Cardiff
University’s animal care committee’s regulations and the
Home Office Animals (Scientific Procedures) Act, 1986
UK.
In situ hybridization (ISH), qPCR, and Western blot
analysis
For all molecular work, mice were sacrificed by carbon
dioxide inhalation and whole brains were extracted. For in
situ hybridization (ISH), whole brains were snap-frozen
and stored at –80°C, while for quantitative real-time PCR
(qRT-PCR) and protein immunoblotting by Western blot-
ting, the whole hippocampus from both brain hemi-
spheres were dissected free-hand and frozen on dry ice
before storage at –80°C.
ISH
Coronal brain sections (14 m) were cut using a cryo-
stat (–20°C, Leica Microsystems) and mounted on poly-
L-lysine coated glass slides. Each slide consisted of one
slice from six separate brains, matched for hippocampal
region (Paxinos and Franklin, 2004) and counterbalanced
across genotype. Two series of the dorsal hippocampus
were produced representing all experimental animals (n
6 per genotype). Slides were fixed in 4% PFA solution,
followed by dehydration in ethanol and stored in 95%
EtOH at 4°C until required. Slides were processed in
parallel as an internal technical control.
The protocol for semi-quantitative ISH using a 3’-end
radiolabeled oligonucleotide (45 mer) with [ɑ-35S]dATP
was broadly similar to previous work (Kirtley and Thomas,
2010; Clifton et al., 2017). Briefly, an oligonucleotide
probe for mouse Gabrd was bioinformatically designed
(NM_008072.2, FASTA, NCBI) to contain 45 base pairs, a
50% AT:CG ratio, contain no more than three consecutive
matching bases and detect all known Gabrd mouse tran-
scripts (NCBI and Ensembl). The Gabrd probe sequence
(3’–5’) was: TCCAT GTCAC AGGCC ACTGT GGAGG
TGATG CGGAT GCTGT ATAAA, binding to the comple-
mentary murine Gabrd nucleotide sequence (nucleotide
position 607–563).
The Gabrd probe was commercially synthesized
(Sigma-Aldrich) and diluted in phosphate buffer (1 g/l,
pH 7) and further diluted to a working concentration of 5
ng/l (in sterile water). Gabrd oligonucleotide probe (1 l)
was added to 6.5 l deionized water, 2.5 l terminal
deoxynucleotidyl transferase buffer (Promega), 1 l termi-
nal deoxynucleotidyl transferase (Promega), and 1 l de-
oxyadenosine 5’-(-thio)triphosphate [35S] (dATP;
PerkinElmer), before being incubated at 30°C for 1 h for
3’-end nucleotide labeling. After incubation, the labeled
nucleotide went through clean-up via Qiaquick Nucleotide
Removal kits (QIAGEN, as per manufacturer’s protocol)
and 2 l dithiothreitol (DTT; 1 M) was added to the eluted
oligonucleotide. Activity of labeledGabrd probe was mea-
sured (HIDEX Triathler liquid scintillation counter) and
within a range of 60,000–250,000 CPM/l.
Three consecutive slides of brain sections (per series)
were selected for ISH, with two slides used to define total
specific (TS) hybridization levels (i.e., technical repeat
included) and 1 slide to define the non-specific (NS) hy-
bridization signal. Radiolabeled probes were applied at a
level of 200,000 cpm per slide. A master mix for the Gabrd
probe was made including radiolabeled probe, 2 l of DTT
(1 M) and 100-l hybridization buffer (HYB) per slide (for
further details on HYB, see Wisden and Morris, 1994).
This master mix solution was applied to two TS slides per
series (100 l/slide), and then unlabeled probe was added
to the remaining master mix (8:1 ratio of unlabeled/labeled
probe) and this was subsequently added to NS allocated
slides (100 l). Parafilm strips were used to form the
necessary matrix for ISH to occur, while all slides were
sealed in humidified plastic chambers and incubated at
42°C overnight. Parafilm coverslips were subsequently
removed in 1  SSC at room temperature (RT). Slides
were then washed in 1 SSC at 52°C for 1 h, rinsed in 0.1
 SSC, and dehydrated in ethanol.
As per Kirtley and Thomas (2010), autoradiographs
were generated using radiographic film exposed to a
quantitative C14 ladder and TS/NS slides for 7 d and
developed. Autoradiograph densitometry was performed
(ImageJ) blind to genotype, whereby NS values were
subtracted from TS values to provide a Specific activity
value, providing a measure of mRNA expression.
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qRT-PCR
RNA was extracted from dissected whole hippocampus
using RNeasy kits (QIAGEN), followed by DNase treat-
ment of RNA (TURBO DNA-free kit, Thermo Fisher Scien-
tific), and converted to cDNA (RNA to cDNA EcoDry
Premix, Random Hexamers, Clontech, Takara). cDNA
samples were prepared in triplicate in 96-well reaction
plates for SYBR-green-based qRT-PCR (SensiFAST, HI-
ROX, Bioline), according to manufacturer’s instructions,
using a StepOnePlus System (Applied Biosystems,
Thermo Fisher Scientific). Gabrd-specific primers, along-
side Gapdh and Hprt primers (housekeeping genes), were
bioinformatically designed to span at least one exon-exon
boundary and to match only for its target mRNA sequence
in mouse (primer-BLAST and nBLAST, NCBI), before be-
ing commercially synthesized (Sigma-Aldrich). Primer ef-
ficiencies were experimentally determined through a
dilution series of experimentally separate WT mouse hip-
pocampal cDNA (efficiency of 90–110% was required,
annealing temperature set at 60°C). All samples were run
in triplicate and individual Ct values (relative to Gapdh
and Hprt) were used to quantify mRNA gene expression.
Primers used for qRT-PCR were as follows: Gabrd, for-
ward GGGCAGAGATGGATGTGAGG and reverse CTT-
GACGACGGGAGATAGCC (targeting exon 8–9); Gapdh,
forward GAACATCATCCCTGCATCCA and reverse
CCAGTGAGCTTCCCGTTCA; and Hprt, forward TT-
GCTCGAGATGTCATGAAGGA and reverse AATGTAATC-
CAGCAGGTCAGCAA.
Immunoblotting by Western blotting
Hippocampal tissue was homogenized manually with a
glass Dounce homogenizer in 1 ml of ice-cold lysis RIPA
buffer (Thermo Fisher Scientific) containing protease in-
hibitors (cOmplete Mini EDTA-free Protease Inhibitor,
Roche, Sigma-Aldrich, 1 tablet/10 ml RIPA). The homog-
enates were centrifuged at 12,000 rpm for 20 min at 4°C
and aliquots of supernatant containing proteins stored at
–80°C. Total protein was quantified using Pierce BCA
Protein kit Assay, as per manufacturer’s instructions
(Thermo Fisher Scientific) and a 1:1 ratio of 40 g of
protein sample was added to 2  Laemmli sample buffer
(containing 1:20 -mercaptoethanol, Bio-Rad). Samples
were denatured at 95°C for 5 min, loaded alternatively by
genotype and separated on a 4–12% gradient Bis-Tris
Midi gel (NuPAGE, Thermo Fisher Scientific) in 1 Bolt
MES SDS Running buffer (Thermo Fisher Scientific) at a
constant voltage of 115 V for 1 h. Transfer was performed
in 1 Bolt Transfer buffer (Thermo Fisher Scientific) to GE
Healthcare Protran nitrocellulose membranes (GE Health-
care Life Sciences) at a constant voltage of 85 V for 2 h 15
min at 4°C.
Blots were blocked in 5% non-fat milk (GE Healthcare
ECL Blocking Agent, GE Healthcare Life Sciences) in 0.1
M Tris-buffered saline solution containing 0.2% Tween 20
(TBST), and this TBST solution was used for all subse-
quent washes. Primary and fluorescent secondary anti-
bodies were similarly diluted in TBST containing 0.2%
Tween 20 and 5% milk and they were used at the follow-
ing concentrations: GABA-A R  (Novus Biologicals,
RRID: AB_2107256), 1:500; calnexin (Abcam, RRID:
AB_2069006), 1:5000; and IRDye 680RD goat anti-rabbit
IgG (Li-Cor, RRID: AB_10956166), 1:15,000. Incubation of
blots in primary antibody solutions were performed at 4°C
overnight, while fluorescent secondary antibodies were
for 1 h at RT. Blots were visualized using the 700-nm
channel of the Odyssey CLx Imaging System (Li-Cor) and
densitometric quantification was performed on scanned
blot films using ImageStudio Lite software (Li-Cor). The
raw fluorescent signal of each GABA-A R  band per
sample was divided by its own protein loading control,
calnexin (with background subtraction). The WTs on the
entire blot were then averaged together and normalized to
100%, while across-blot variance was minimized by giv-
ing each individual Cyfip1/– signal relative to the aver-
aged total of all WT lanes.
Brain slice preparation and electrophysiology
Animals of either sex were deeply anaesthetized using
isoflurane, decapitated and their brains removed into
chilled (1–3°C) cutting solution containing 60 mM sucrose,
85 mM Nacl, 2.5 mM KCl, 1 mM CaCl2, 2 mM MgCl2, 1.25
mM NaH2PO4, 25 mM NaHCO3, 25 mM D-glucose, 3 mM
kynurenic acid, and 0.045 mM indomethacin. Horizontal
hippocampal brain slices (300 m) containing the DG
were prepared from adolescent and adult WT and
heterozygous Cyfip1 and PVTdCyfip1 mice, stored for
20 min at 35°C in sucrose-containing solution and sub-
sequently maintained at RT in artificial CSF (aCSF) con-
taining 125 mM NaCl, 2.5 mM KCl, 1 mM CaCl2, 1 mM
MgCl2, 1.25 mM NaH2PO4, 25 mM NaHCO3, and 25 mM
D-glucose (305 mOsm) then used within 4–6 h. For re-
cording, slices were transferred to a submersion chamber
continuously perfused with warmed (33–34°C) aCSF con-
taining 125 mM NaCl, 2.5 mM KCl, 2 mM CaCl2, 1 mM
MgCl2, 1.25 mM NaH2PO4, 25 mM NaHCO3, 25 mM D-
glucose, and 3 mM kynurenic acid (305–310 mOsm, pH
7.4) at a flow rate of 3 ml min1. Electrophysiological
recordings were performed on DGGCs and PV-INs of
the DG GCL. DGGCs were identified using Dodt-contrast
video microscopy and PV-INs were identified by their
expression of the red fluorescent protein tdTomato fol-
lowing two-photon excitation at   900 nm (Prairie Ul-
tima two-photon microscope, Bruker). Whole-cell voltage
clamp recordings were made using a Multiclamp 700B
(Molecular Devices) patch clamp amplifier with patch pi-
pettes with resistances between 3 and 6 M when filled
with an internal recording solution containing 130 mM
CsCl, 2 mM MgCl2, 4 mM Mg-ATP, 0.3 mM Na-GTP, 10
mM HEPES, and 0.1 mM EGTA (295 mOsm, pH 7.3)
supplemented with Alexa Fluor 594 (DGGC, 50 M, Life
Technologies) or Alexa Fluor 488 (PV-IN, 100 M, Life
Technologies). All experiments were performed at a holding
potential (Vh) of –70 mV unless specifically indicated else-
where. Series resistance (RS) was compensated by 80%and
cells showing changes of RS 	20% over the course of the
experiment were rejected. Data were sampled at 20 kHz
a nd l ow - p a s s f i l t e r e d a t 6 kH z . 4 , 5 , 6 , 7 -
tetrahydroisoxazolopyridin-3-ol (THIP, Gaboxadol), 1,2,5,6-
tetrahydro-1-[2-[[(diphenylmethylene)amino]oxy]ethyl]-3-
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pyridinecarboxylic acid hydrochloride (NNC711, NO711),
N,N,6-trimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-
acetamide (Zolpidem), and picrotoxin (PTX) were obtained
from Tocris Bio-techne.
Data analysis and statistics
Spontaneous IPSCs (sIPSCs) were detected using a
template search routine in pClamp 10 (Clampex, Molec-
ular Devices) and their amplitude, frequency and integral
were measured. IPSCs were automatically detected from
a 20- to 60-s control baseline period and manually in-
spected post hoc for false event detection. For analysis of
event frequency, the simple mean arithmetic IPSC fre-
quency for each cell was calculated as the number of
IPSCs detected divided by the length of the sampling
period. The instantaneous frequency was calculated as
1/inter-IPSC interval of all recorded IPSCs. Occasional
unclamped action currents were detected and these were
rejected from analysis. For analysis of IPSC decay, events
whose decay phase were contaminated by other IPSCs
were rejected and remaining events were averaged to
produce a single averaged IPSC for each cell. Each aver-
aged IPSC was fitted with a double exponential function
with two amplitude components (A and B) and two decay
time constants (1 and 2) to calculate the weighted decay
time constant (W) by W  [(A/A  B) 1]  [(B/B  A) 2].
The mean charge carried by individual IPSCs (in pC) for
each cell was the integral of the averaged IPSC calculated
by multiplying the amplitude of the averaged IPSC for
each cell by its W. The total IPSC charge delivered was
the mean IPSC charge multiplied by the arithmetic IPSC
frequency. To measure tonic GABAA currents the mean
holding current at Vh –70 mV in the absence and presence
of drugs was measured by fitting a single Gaussian func-
tion to all-points histograms constructed from five one
second long sampling periods (Bright and Smart, 2013).
The holding current for each condition was measured as
the mean of the Gaussian distribution and the root mean
square (RMS) noise was the standard deviation of the
distribution. To account for the hierarchical structure of
the data and non-independencies within it (see Results;
Fig. 1E), the amplitudes and instantaneous frequencies of
IPSCs in DGGCs and PV-INs were analyzed using a
linear mixed effects (LMEs) model constructed in the
open-source statistical software environment R (R Core
Team, 2018) using the lme4 module (Bates et al., 2015).
The model used for the analysis was a random intercept
model including a single fixed effect (genotype: WT vs
Cyfip1/–) and two random effects accounting for varia-
tion between cells and between mice. The linearity and
homoskedasticity of the data were confirmed by plotting
the residuals obtained from the fitted model. Data ob-
tained for both IPSC amplitudes and instantaneous fre-
quencies we found to follow lognormal distributions. LME
models were therefore fit to the natural logarithm [ƒ(x) 
ln(x), x 	 0] transformed IPSC amplitude and instanta-
neous frequency data which followed approximately nor-
mal distributions (Figs. 1, 3). Subsequently, mean () IPSC
amplitude (in pA) and frequency (in Hz) for each genotype
were obtained by inverting the intercept values obtained
from the LME models (fitted to log-transformed data)
using the exponential function [ƒ1()  e]. Thus, the
mean values reported for IPSC amplitude and instanta-
neous frequency are the geometric rather than arithmetic
means of the data. The geometric mean of the log-
normally distributed data represents the “central ten-
dency” of the data better than the arithmetic mean and
gives a more accurate measure of the typical event with-
out the distorting effect of the relatively small number of
large amplitudes or high instantaneous frequencies IPSCs
that skew the distribution. The geometric mean IPSC
amplitudes and instantaneous frequencies obtained using
this approach are reported with their 95% confidence
intervals (95% CIs) which are asymmetric around the
mean. Upper and lower confidence limits were calculated
as the exponential [ƒ(CI)  eCI] of the mean plus or minus
1.96 times the standard error of the intercept vales ob-
tained from the LME model fits. The effect of genotype on
IPSC amplitude/frequency was tested using the “anova()”
function in R (likelihood ratio test) to compare our model
with a null model which excluded the fixed effect. Unless
otherwise indicated, n refers to the number of cells re-
corded under each condition. For each condition cells
were sampled from a minimum of 3 different non-
littermate mice for each genotype. Data analysis was
performed using pClamp 10 (Molecular Devices), Prism 5
(GraphPad) software and R (https://www.R-project.org/).
Statistical testing was by paired/unpaired t test or one-
way ANOVA where appropriate and as indicated in text.
For ISH, qRT-PCR and immunoblotting techniques,
outliers 	2.5 SD from the mean were removed and sig-
nificance was determined by one-way or two-way ANOVA
using SPSS software (IBM, v.20). Post hoc Dunnett’s
multiple comparison procedure was applied to data which
surpassed significance threshold (  0.05) in ANOVA, to
determine specific group differences. Detailed statistical
analyses can be found in the figure legends. All values are
given as mean 
 SEM, with the exception of qRT-PCR
data given as mean 
 SD.
Results
GABAergic inhibition is unaltered in DGGCs of
Cyfip1/– mice
We performed whole-cell voltage clamp recordings
from DGGCs to determine the effects of Cyfip1 haploin-
sufficiency on GABAergic inhibition. To confirm that all
DGGCs we recorded from were fully mature neurons, and
not from immature adult born granule cells, we first per-
formed current clamp recordings on a subset (n  4) of
DGGCs. This revealed, as shown previously, that cells
with mature morphology and dendrites projecting into the
outer molecular layer (ML; Fig. 1A) also displayed firing
properties and input resistances characteristic of mature
cells (300 M; Fig. 1B). Thus, in subsequent voltage
clamp experiments, we considered recorded cells to be
fully mature granule cells based on inspection of their
morphology after filling with Alexa Fluor 594. First, we
measured properties of synaptic inhibition in DGGCs by
recording sIPSCs. In control cells, from WT mice, our
recordings revealed that sIPSCs properties were similar to
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Figure 1. IPSCs in DGGCs of WT and Cyfip1/– mice. A, Dodt gradient contrast image of a horizontal section of the hippocampus.
Dashed lines illustrate the border between the ML, GCL, and subgranular zone (SGZ). Patch pipette filled with Alexa Fluor 594 (left)
illustrates the position of a mature DGGC (right), imaged by two-photon microscopy, with dendrites projecting to the edge of the ML.
B, Traces depicting typical electrophysiological properties of a mature DGGC. C, A typical voltage clamp recording showing IPSCs
from DGGC of WT mouse and the averaged IPSC from this cell. Inset schematic shown here and elsewhere signifies data recorded
DGGC. D, A typical voltage clamp recording showing IPSCs from DGGC of Cyfip1/– mouse and the mean IPSC from this cell. E,
Histograms showing the mean (red/blue lines) and standard deviation (light blue/red shading) of the log–normal distribution of all IPSC
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those reported for DGGC in previous studies, consistent
with a large proportion of their inhibitory input coming
from local fast-spiking interneurons (Fig. 1C; Bartos et al.,
2001; Nusser and Mody, 2002; Chandra et al., 2006).
First, we analyzed the effect of genotype on IPSC ampli-
tudes in DGGCs. We found that the amplitudes of sam-
pled IPSCs in both WT and Cyfip1/– DGGCs were
approximately log-normally distributed (Fig. 1E). Thus, for
subsequent analysis we used the corresponding log-
transformed data which followed a normal distribution
(Fig. 1F). Since many individual IPSCs were recorded from
each neuron (i.e., repeated measures) and several neu-
rons recorded from individual mice (Fig. 1E,F) it is clear
our data violates the critical assumption of independence
required for linear modeling. Therefore, we chose to fit the
log-transformed IPSC amplitudes, pooled from all re-
corded DGGCs (WT: 9494 IPSCs from 25 cells/five mice,
Cyfip1/–: 4948 IPSCs from 14 cells/four mice), using a
LMEs model. Using LME models allows us to analyze the
effects of genotype across our entire sample of IPSCs
while accounting for the non-independencies that result
from the hierarchical structure of our data. An example of
the hierarchical structure within the data can be seen in in
the scatterplot shown in Figure 1E, which shows individ-
ual IPSCs grouped by neuron, by mouse and by geno-
type. In our analysis, the LME models we have used
account for the random variation across individual neu-
rons and individual mice allowing us to isolate the effect of
genotype on the dependent variable (IPSC amplitude/
frequency). Using this approach we found that genotype
did not significantly affect the amplitude of IPSCs in
DGGC (	2(1)  0.06, p  0.80) with WT IPSCs having a
mean amplitude of 25.7 pA (95% CI: 21.1, 31.2) and
Cyfip1/– IPSCs having an amplitude of 26.3 pA (95% CI:
22.6, 30.6). Moreover, we found no significant differences
in the weighted decay time constant (W; p  0.70, un-
paired t test; Table 1; Fig. 1C,D) and charge transfer (p 
0.95, unpaired t test; Table 1) for averaged IPSCs be-
tween Cyfip1/– mice and their WT counterparts. Simi-
larly, we also found that the instantaneous frequencies
(1/inter-IPSC interval) of both WT and Cyfip1/– IPSCs
were log-normally distributed (Fig. 1G) and that their cor-
responding log-transformed values were normally distrib-
uted (Fig. 1H). Fitting an LME model revealed that
genotype had no significant effect on IPSC instantaneous
frequency (	2(1)  0.67, p  0.41) with WT IPSCs having
a mean frequency of 7.42 Hz (95% CI: 6.44, 8.55) and
Cyfip1/– IPSCs having a frequency of 6.86 Hz (95% CI:
5.74, 8.18), respectively. Thus, we find that haploinsuffi-
ciency of Cyfip1 does not impair phasic GABAergic inhi-
bition in DGGC of the mouse hippocampus.
However, as discussed earlier, FMRP can reduce tonic
inhibition through mechanisms that are not dependent on
changes in presynaptic neurotransmitter release, in par-
ticular, a direct postsynaptic reduction of the expression
of GABAAR -subunits (D’Hulst et al., 2006; Curia et al.,
2009; Zhang et al., 2017). To test whether the loss of one
Cyfip1 allele and reduction in expression of the FMRP
binding partner CYFIP1, which mimics microdeletion at
locus 15q11.2 in humans, produces a similar reduction in
GABAAR -subunit-dependent tonic inhibition as ob-
served in FXS, we evoked currents using the -subunit-
selective drug THIP (Gaboxadol). We measured THIP-
evoked currents using both the drug-induced shift in
holding current and difference in RMS noise as the latter
has been suggested to be more sensitive to detecting
small differences in tonic inhibition (Bright and Smart,
2013). To evoke sufficiently large currents to allow us to
easily compare between genotypes we used THIP at
concentrations of 3 and 10 M. At 3 M, THIP is largely
selective for high affinity -subunit-containing receptors,
whereas at 10 M it may also substantially activate
-subunit-lacking receptors (i.e.,  pentamers; Meera
et al., 2011). This approach allowed us to investigate
differences in both of the potential pools of extrasynaptic
receptors in these cells across genotypes. In DGGCs from
WT animals, bath application of THIP produced a con-
centration dependent increase in the current required to
hold the cell at –70 mV (ITHIP; WT: ITHIP 3 M: 54.8 
 4.4
pA, n  7; ITHIP 10 M: 102.5 
 5.6 pA, n  15; Fig. 2A,C)
continued
amplitudes recorded in WT and Cyfip1/– DGGC. Scatter plot shows the amplitude of individual IPSCs grouped by cell, mouse, and
genotype. Individual IPSCs from each cell are shown as aligned dots (light blue/red) with the mean IPSC amplitude for each cell shown
as an unfilled superimposed square (red/blue). Varying length vertical lines (blue/red) represent the mean IPSC amplitude for each
animal with the length of the bar illustrating the number of recorded neurons from each mouse. Red/blue symbols (top) are the
arithmetic mean and standard deviation of the complete dataset for each genotype. F, As in E but for log-transformed IPSC amplitude
data. G, As in E but for IPSC instantaneous frequency data. H, As in E but for log-transformed IPSC frequency data.
Table 1 IPSC properties in DGGCs and PV-INs of WT and Cyfip1/– mice
n Peak amplitude (pA) Weighted decay (ms)
Frequency
(Hz)
Charge
transfer (fC)
Total IPSC
charge (pC)
DGGC
WT 25 29.5 
 1.8 4.4 
 0.1 6.3 
 0.4 128.8 
 8.3 0.87 
 0.1
Cyfip1/- 14 29.7 
 2.2 4.3 
 0.1 5.9 
 0.5 127.9 
 10.3 0.76 
 0.1
PV-INs
WT 18 44.9 
 4.2 1.8 
 0.2 25.1 
 2.1 82.2 
 11.5 2.28 
 0.5
Cyfip1/- 13 44.0 
 4.0 2.0 
 0.2 27.9 
 2.4 87.8 
 9.9 2.54 
 0.4
n  number of neurons from a minimum of three mice per genotype.
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Figure 2. THIP-evoked currents in DGGC of WT and Cyfip1/– mice. A, Trace showing PTX-sensitive concentration-dependent
THIP-evoked currents in a DGGC from aWTmouse. All-points histogram illustrates the shift in holding current and RMS noise induced
by THIP and PTX. B, As in A for DGGC in Cyfip1/– mouse. C, Scatter plot summarizing the THIP-evoked currents in WT (blue) and
Cyfip1/– DGGC. D, Scatter plot summarizing membrane capacitance of WT (blue) and Cyfip1/– DGGC. E, Scatter plot summarizing
the THIP-evoked changes in RMS noise in WT (blue) and Cyfip1/– DGGC. F, Scatter plot summarizing the normalized (pA/PF)
THIP-evoked current in WT (blue) and Cyfip1/– DGGC.
Negative Results 8 of 20
May/June 2019, 6(3) ENEURO.0364-18.2019 eNeuro.org
and a corresponding increase in RMS noise (WT: RMS-
control: 4.24 
 0.15 pA, n  15; RMSTHIP 3 M: 8.39 
 0.35
pA, n  7; RMSTHIP 10 M: 11.81 
 0.33 pA, n  15; Fig.
2A,E) indicating increased opening of -subunit-
containing eGABAARs. The THIP-evoked currents were
completely blocked by the GABAA channel blocker PTX
(100 M) confirming their GABAergic nature (Fig. 2A). We
observed a very slight, but not significant, reduction in
both the magnitude of ITHIP (Cyfip1
/–: ITHIP 3 M: 50.6

2.5 pA, n  10, p  0.39, ITHIP 10 M: 90.0 
 5.3 pA, n 
10, p  0.14, unpaired t test; Fig. 2B,C) and RMS noise
(Cyfip1/–: RMScontrol: 4.25 
 0.14 pA, n  10, p  0.96;
RMSTHIP 3 M: 7.90 
 0.31 pA, n  10, p  0.31; RMSTHIP
10 M: 11.06 
 0.52 pA, n  10, p  0.21; Fig. 2B,E) in
Cyfip1/– compared to WT DGGCs. To confirm that the
lack of observed difference in ITHIP was not due to a
compensatory change resulting from a genotype depen-
dent change in dendritic size or complexity we normalized
the evoked currents per pF of membrane capacitance
(Cm). Although we observed no significant (p  0.47,
unpaired t test) difference in Cm between WT (9.4 
 0.4
pF, n  15) and Cyfip1/– (10.0 
 0.8 pF, n  10) DGGCs
(Fig. 2D), normalization of ITHIP to Cm revealed a trend
toward a reduction in THIP-evoked currents in Cyfip1/–
DGGC (ITHIP 3 M: 5.2 
 0.2 pA/pF, n  10; ITHIP 10 M:
9.3 
 0.6 pA/pF, n  10) compared to WT DGGC (ITHIP
3 M: 6.2 
 0.2 pA/pF, n  7, p  0.01; ITHIP 10 M: 11.0

 0.5 pA/pF, n  15, p  0.06; Fig. 2F), although the
difference was small and only statistically significant for
the lower concentration of THIP. Finally, to determine
whether changes in tonic inhibition might occur later in
life, we performed recordings from a small number of
adult WT and Cyfip1/– mice (n  2 mice per genotype).
Similarly to the findings in adolescent mice, we found
currents evoked by 3 M THIP were not significantly
different between genotypes in DGGCs of older mice (WT:
ITHIP 3 M: 62.9 
 5.9 pA, n  9; Cyfip1
/–: ITHIP 3 M:
70.3 
 7.1 pA, n  9, p  0.44, unpaired t test). Thus,
overall, we conclude that haploinsufficiency of Cyfip1
does not significantly alter GABAergic inhibition in DG-
GCs of the mouse hippocampus.
GABAergic inhibition is unaltered in GCL PV-INs of
Cyfip1/– mice
As well as DGGCs, detailed immunohistochemical
studies have identified that interneurons of the DG also
express GABAAR -subunits. In particular, PV
-INs found
in the GCL and SGZ of the DG have 100% co-expression
of parvalbumin and GABAAR -subunits (Milenkovic et al.,
2013). However, it remains to be demonstrated that PV-
INs in these layers express functional -subunit-
dependent tonic GABAergic currents. Since PV-INs
have been previously implicated as key targets in neuro-
psychiatric disorders, we tested for the functional pres-
ence of eGABAergic inhibition in these cells in Cyfip1/–
and WT mice. To do this, we crossed a PV-Cre mouse
with a tdTomato reporter mouse line and subsequently
the Cyfip1/– mouse (PVTdCyfip1) and made targeted
patch clamp recordings from GCL PV-INs (Fig. 3A).
Current-clamp recordings from GCL PV-INs (n  3)
showed that these PV cells had firing properties, typical
of fast-spiking basket cells including high frequency firing
and action potentials with characteristic short half-widths
(Fig. 3B). First, we compared phasic GABAergic inhibition
in GCL PV-INs in Cyfip1/– and WT mice. Consistent
with previous studies, IPSCs in PV-INs decayed more
rapidly than those recorded in DGGC with significantly
shorter decay time constants (W; WT: DGGC: 4.4 
 0.1
ms, n  25, WT: PV-IN: PV-IN 1.8 
 0.2 ms, n  18, p
 0.0001, unpaired t test; Table 1; Fig. 3C,D). This can be
seen clearly in the overlaid traces shown in Figure 3C,D
and is consistent with a higher level of expression of
1-subunits in PV
-INs compared to DGGCs (Bartos
et al., 2001, 2002). Similarly, to DGGCs, IPSC amplitudes
(Fig. 3E) and instantaneous frequencies (Fig. 3G) in PV-
INs were found to be log-normally distributed. Therefore,
we fit LME models to the log-transformed data values,
which were approximately normally distributed (Fig.
3F,H), to account for the hierarchical structure of the data
as depicted in the scatterplots in Figure 3F,H. As for
DGCGs, we found that genotype had no effect on IPSC
amplitudes in PV-INs (	2(1)  0.03, p  0.86) with WT
IPSCs (n  14,358 IPSCs from 18 cells/five mice) having
a mean amplitude of 39.3 pA (95% CI: 30.3, 50.9) and
Cyfip1/– IPSCs (n  6881 IPSCs from 13 cells/four mice)
having a mean amplitude of 40.2 pA (95% CI: 33.0, 49.0).
We also found no significant difference in the weighted
decay time constant (W; p  0.32, unpaired t test;
Table 1; Fig. 3C,D) and charge transfer (p  0.73, un-
paired t test; Table 1) for IPSCs between Cyfip1/– mice
and WT littermates. In comparison to DGGC, PV-INs had
an 4-fold higher arithmetic mean IPSC frequency
(Table 1; Fig. 3C,F). Fitting an LME model to the log-
transformed PV-IN IPSC instantaneous frequency data
revealed a mean WT IPSC instantaneous frequency of
32.1 Hz (95% CI: 25.1, 41.0) compared to a mean Cy-
fip1/– IPSC frequency of 35.9 Hz (95% CI: 29.9, 43.3).
Genotype did not significantly (	2(1)  0.81, p  0.37)
affect IPSC instantaneous frequency in PV-INs. Thus, as
with DGGCs, we conclude that Cyfip1 haploinsufficency
does not change the properties of IPSCs in PV-INs of the
DG.
Unlike DGGCs, it remains to be demonstrated whether
PV-INs in the GCL of the DG express functional -subunit-
containing eGABAARs and have tonic GABAergic inhibi-
tion. Therefore, we next used THIP to demonstrate the
presence of these receptors in molecularly identified GCL
PV-INs and to compare their relative activation in Cy-
fip1/– and WT cells. In WT PV-INs, THIP produced a
concentration-dependent PTX-sensitive increase in hold-
ing current (WT: ITHIP 3 M: 58.5 
 11.9 pA, n  6; ITHIP
10 M: 161.6 
 27.2 pA, n  6; Fig. 4A,C) that was
accompanied by a marked increase in RMS noise (WT:
RMScontrol: 6.92 
 0.36 pA, n  6; RMSTHIP 3 M: 10.33 

1.29 pA, n  6; RMSTHIP 10 M: 13.15 
 1.66 pA, n  6;
Fig. 4A,E) demonstrating the presence of -subunit-
containing eGABAARs. However, we found no significant
difference in the magnitude of THIP-evoked currents (Cy-
fip1/–: ITHIP 3 M: 56.6 
 7.6 pA, n  8, p  0.71; ITHIP
10 M: 174.2 
 19.9 pA, n  8, p  0.89, unpaired t test)
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Figure 3. IPSCs in GCL PV-INs of WT and Cyfip1/– mice. A, Dodt gradient contrast image of a horizontal section of the
hippocampus. Dashed lines illustrate the border between the ML, GCL, and SGZ. An example of PV-INs in the DG GCL identified
by expression of the red fluorescent protein tdTomato filled via the recording electrode with Alexa Fluor 488 (right). B, Traces depicting
typical electrophysiological properties of a GCL PV-INs. Inset shows the shorter half-width of a typical PV-IN action potential
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or changes in RMS noise (Cyfip1/–: RMScontrol: 7.44 

0.30 pA, n  8, p  0.29; RMSTHIP 3 M: 10.94 
 0.55 pA,
n  8, p  0.64; RMSTHIP 10 M: 15.09 
 1.00 pA, n  8,
p  0.31, unpaired t test; Fig. 4B,E) in Cyfip1/– PV-INs
compared to WT controls. We found, as measured by cell
capacitance, that GCL PV-INs were approximately three
times larger than DGGCs but that there was no difference
in cell size between genotypes (WT: 31.8 
 4.0 pF, n  6,
Cyfip1/–: 30.1
 1.87 pF, n 8, p 0.68, unpaired t test;
Fig. 4D). Consequently, when normalized to cell capaci-
tance no difference in THIP-evoked currents in WT (ITHIP
3 M: 2.0
 0.4 pA/pF, n 6; ITHIP 10 M: 5.4
 1.0 pA/pF,
n 6) compared toCyfip1/– (ITHIP 3 M: 1.8
 0.2 pA/pF,
n  8, p  0.80, ITHIP 10 M: 5.7 
 0.4 pA/pF, n  8, p 
0.73, unpaired t test) PV-INs was observed. Thus, simi-
larly to DGGCs, haploinsufficiency of Cyfip1 does not
significantly alter GABAergic inhibition in GCL PV-INs of
the mouse hippocampus.
mRNA expression and protein levels of  and other
key GABAAR subunits in hippocampus
To confirm our electrophysiological findings, we first
measured the expression level of the GABAAR -subunit
(encoded by Gabrd) in adult WT and Cyfip1/– mice.
Using ISH techniques, we measured GABAAR -subunit
mRNA expression in three major subfields of the hip-
pocampus including the DG (CA1, CA3, DG; Fig. 5A). We
confirmed, as shown previously (Pirker et al., 2000; Zheng
et al., 2009; Milenkovic et al., 2013; Fritschy and Pan-
zanelli, 2014), that the majority of GABAAR -subunit ex-
pression occurs in the DG with little -subunit expression
in the CA1 and CA3 hippocampal subfields (brain region:
F(2,30)  55.370, p  0.0001, two-way ANOVA; post hoc
Dunnett’s test show DG v CA1 and DG v CA3 were both
p  0.0001). Significantly, we observed no influence of
Cyfip1 haploinsufficiency on GABAAR -subunit mRNA
expression and its distribution across the hippocampus
(genotype: F(1,30)  1.656, p  0.208; genotype  brain
region F(2,30)  0.006, p  0.994, two-way ANOVA). The
lack of change in GABAAR -subunit expression was
confirmed by complementary qRT-PCR techniques per-
formed in the whole hippocampus of adult WT and Cy-
fip1/– mice (Gabrd exp: F(1,26)  2.526, p  0.124, one-
way ANOVA; Fig. 5B).
We next measured the mRNA expression of GABAAR
4-subunits (Gabra4), which are co-expressed with
-subunits in the majority, if not all, eGABAAR in DGGC
(Sun et al., 2004; Chandra et al., 2006). Consistent with a
lack of change in -subunit expression, we found no
significant difference in the 4-subunit expression in hip-
pocampus of adult WT and Cyfip1/– mice (Gabra4 exp:
F(1,25)  0.105, p  0.749, one-way ANOVA, 1 outlier
removed; Fig. 5B). This was in agreement with unaltered
GABAergic inhibition in DGGC (Figs. 1, 2). Furthermore,
we assessed the expression of GABAAR 1-subunits (Ga-
bra1) in WT and Cyfip1/– mice, since these subunits can
also form high affinity GABAAR with -subunits (Glykys
et al., 2007; Karim et al., 2013) and are highly expressed
in GCL PV-INs (Milenkovic et al., 2013). In line with our
electrophysiological observations (Fig. 3), which showed
no difference in tonic inhibition in PV-INs, we found no
difference in 1-subunit expression in adult WT and Cy-
fip1/– mice (Gabra1 exp: F(1,26)  0.849, p  0.365,
one-way ANOVA; Fig. 5B).
Lastly, to complement the majority of our electrophys-
iological work, which was conducted in adolescent rather
than adult mice, we extended our analysis of GABAAR
-subunit expression into adolescent WT and Cyfip1/–
mice. Our data confirmed that hippocampal GABAAR
-subunit mRNA expression (Gabrd mRNA exp: F(1,18) 
0.545, p  0.470, one-way ANOVA; Fig. 5C) and protein
levels were also unaffected by Cyfip1 haploinsufficiency
(Gabrd protein: F(1,15)  0.221, p  0.221, one-way
ANOVA; Fig. 5D) in adolescent mice.
Tonic inhibition in GCL PV-INs involves 1-subunit-
containing eGABAARs
Although we found no significant difference in THIP-
evoked currents in molecularly defined GCL PV-INs be-
tween Cyfip1/– and WT mice, our data demonstrates for
the first time to our knowledge, the presence of functional
tonic GABAergic inhibition in these GCL interneurons.
Consequently, we decided to further characterize the
tonic GABA currents in these interneurons and compare
them with their neighboring granule cells. Therefore, we
first measured basal tonic current in both PV-INs and
DGGCs in WT mice under our in vitro conditions using the
GABA channel blocker PTX (100 M). In DGGCs, appli-
cation of PTX produced a significant reduction in the
holding current (Table 2) of 12 
 2.5 pA (Fig. 6A,D) which
was accompanied by a reduction in RMS noise of 1.98 

0.33 pA (Fig. 6A,F). The tonic current we recorded under
basal conditions in DGGC was similar to that previously
reported for these cells (Nusser and Mody, 2002; Chandra
et al., 2006; Wlodarczyk et al., 2013). On the other hand,
basal tonic currents in PV-INs (34.9 
 3.5 pA, n  4)
continued
compared to that of a typical DGGC. C, Voltage clamp recording showing IPSCs from PV-INs of WT mouse and the averaged IPSC
from this cell. Inset schematic shown here and elsewhere signifies data recorded PV-INs. D, A typical voltage clamp recording
showing IPSCs from PV-INs of Cyfip1/– mouse and the mean IPSC from this cell. E, Histograms showing the mean (red/blue lines)
and standard deviation (light blue/red shading) of the log –normal distribution of all IPSC amplitudes recorded in WT and Cyfip1/–
PV-INs. Scatter plot shows the amplitude of individual IPSCs group by cell, mouse, and genotype. Individual IPSCs from each cell
are shown as aligned dots (light blue/red) with the mean IPSC amplitude for each cell shown as an unfilled superimposed square
(red/blue). Varying length vertical lines (blue/red) represent the mean IPSC amplitude for each animal with the length of the bar
illustrating the number of recorded neurons from each mouse. Red/blue symbols (top) are the arithmetic mean and standard deviation
of the complete dataset for each genotype. F, As in E but for log-transformed IPSC amplitude data. G, As in E but for IPSC
instantaneous frequency data. H, As in E but for log-transformed IPSC frequency data.
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Figure 4. THIP-evoked currents in PV-INs of WT and Cyfip1/– mice. A, Trace showing PTX-sensitive concentration-dependent
THIP-evoked currents in a PV-IN from a WT mouse. All-points histogram illustrates the shift in holding current and RMS noise
induced by THIP and PTX. B, As in A for PV-INs in Cyfip1/– mouse. C, Scatter plot summarizing the THIP-evoked currents in WT
(blue) and Cyfip1/– PV-INs. D, Scatter plot summarizing membrane capacitance of WT (blue) and Cyfip1/– PV-INs. E, Scatter plot
summarizing the THIP-evoked changes in RMS noise in WT (blue) and Cyfip1/– DGGC. F, Scatter plot summarizing the normalized
(pA/PF) THIP-evoked current in WT (blue) and Cyfip1/– DGGC.
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Figure 5. Molecular assessment of  and other key GABAA subunits in WT and Cyfip1
/– mice. A, mRNA expression of  GABAA
subunit (Gabrd) in hippocampal subfields (CA1, CA3, DG) of WT and Cyfip1/– adult mice were measured by ISH and given as
absolute mean optical density values 
 SEM (n  6 per genotype). Once ANOVA revealed a main effect for brain region, Dunnett’s
test was used for post hoc analysis to determine the sources of significance (DG vs CA1 and DG vs CA3, p  0.0001).
Representative autoradiographs show two coronal WT mouse brain sections hybridized with an oligonucleotide probe targeting
Gabrd. B, Expression of GABAA -, 4-, and 1-subunits (equivalent to Gabrd, Gabra4, and Gabra1 genes) were measured by
qRT-PCR mRNA expression in adult whole hippocampus and given as mean delta Ct values 
 SD relative to two housekeeping
genes, Gapdh and Hprt (n  14 per genotype, 1 outlier removed in Gabra4 data). C, As in B, qRT-PCR was used to measure Gabrd
mRNA expression in juvenile WT and Cyfip1/–mice (n 10 per genotype). D, Hippocampal protein levels of GABAA were measured
by immunofluorescent Western blotting in WT and Cyfip1/– mice. Cyfip1/– densitometric data given relative to the average of all WT
samples (100%) and normalized to protein loading control, calnexin (WT: n  9, Cyfip1/–: n  8). Representative immunofluorescent
blot shows Gabrd and calnexin bands in WT and Cyfip1/– mouse samples.
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were 3-fold greater than those we observed in DGGCs
(Table 2; Fig. 6A,D). However, when normalized to cell
capacitance, the tonic current density was not signifi-
cantly different in PV-INs (1.21 
 0.09 pA/pF, n  4)
compared to DGGCs (1.45
 0.38 pA/pF, n 5, p 0.61,
unpaired t test; Fig. 6E). Interestingly, when the fraction of
total GABAergic inhibition provided by tonic inhibition
versus phasic IPSCs is compared between DGGCs and
PV-INs, we find remarkable similarity between the cell
types. The mean total charge was calculated as the sum
of the total charge provided by IPSCs (Table 1) plus the
charge provided by tonic inhibition. For DGGCs, IPSCs
provided 6.7% of the total inhibitory charge (0.87 pC of
12.97 pC total charge), and for PV-INs, IPSCs provided
6.1% of the total inhibitory charge (2.28 pC of 37.18 pC
total charge). The similarity between these values and
their similarity to the fraction of inhibitory charge provided
by tonic inhibition in other cell types (Brickley et al., 1996;
Rossi et al., 2003; Cope et al., 2005) suggests that ex-
pression of eGABAAR might be regulated to constrain the
ratio of tonic to phasic inhibition within fairly narrow
bounds across both inhibitory and excitatory neurons and
this might be critical for stability of neuronal input-output
transformations (Pavlov et al., 2009).
So far, we have shown that GCL PV-INs are regulated
by tonic GABAergic inhibition, as evidenced by their sen-
sitivity to PTX, and that the eGABAAR underlying this tonic
inhibition contain GABAAR -subunits as revealed by their
sensitivity to the agonist THIP. However, previous histo-
logic experiments have shown that PV-INs have high
expression of 1 GABAAR subunits and weaker expres-
sion of 4-subunits which predominate in DGGC (Sun
et al., 2004; Chandra et al., 2006; Milenkovic et al., 2013).
It has previously been shown that 1-subunits can form
receptors with -subunits but that these receptors have a
markedly lower affinity for GABA than 4 containing re-
ceptors (Karim et al., 2013). Therefore, we next compared
how tonic inhibition in PV-INs and DGGCs is changed by
alterations in the extracellular GABA concentration. To do
this we applied the GAT-1 inhibitor NNC-711 (10 M)
along with 5 M GABA to elevate the concentration of
GABA in the extracellular environment. In both cell types,
bath application of NNC-711/GABA significantly in-
creased the holding current (Table 2; Fig. 6B,D) and RMS
noise (Table 2; Fig. 6B,F) compared to control demon-
strating that tonic inhibition in PV-INs, like DGGCs, is
regulated by the GABA concentration in the extracellular
space. Interestingly, the increase in tonic current was
significantly larger in DGGCs compared to PV-INs (Fig.
6B,D–F), suggesting that the former express eGABAAR
with higher affinity for GABA and are more sensitive to
changes in extracellular GABA as would be expected for
4 containing receptors versus 1 containing ones (see
Discussion).
Consequently, we next directly tested whether GCL
PV-INs express eGABAAR containing 1-subunits using
the 1-selective non-benzodiazepine drug zolpidem. It is
already established in DGGC that, although it modulates
phasic inhibition by prolonging IPSC time constants, zol-
pidem does not modulate tonic inhibition due to its lack of
effect at 4 containing eGABAARs (Nusser and Mody,
2002). We confirmed that application of 0.5 M zolpidem
did not significantly change the holding current (Ihold
ZOLP: –4.4 
 3.1 pA) or RMS noise (RMS ZOLP: –0.86

 0.17 pA) in DGGC (Table 2; Fig. 6C–F). On the other
hand, we found that bath application of zolpidem to PV-
INs produced a significant increase in the holding current
(Ihold ZOLP: 23.9 
 3.8 pA) and RMS noise (RMS
ZOLP: 1.61 
 0.61 pA; Table 2; Fig. 6C–F). Thus, we
conclude that molecularly defined PV-INs in the DG GCL
receive tonic GABAergic inhibition which is mediated by
eGABAARs containing - and 1-subunits.
Discussion
Haploinsufficiency of Cyfip1 does not alter
GABAergic inhibition in DG
Loss of FMRP causes FXS and is associated with dis-
rupted GABA signaling throughout the brain involving
both pre- and postsynaptic mechanisms (Deng et al.,
2011; Kang et al., 2017; Sabanov et al., 2017). A key
binding partner of FMRP, CYFIP1, is encoded by the
CYFIP1 gene which is found at the 15q11.2 locus in
humans. CNVs at this locus have been shown to signifi-
Table 2. Pharmacologically induced changes in holding current in DGGCs and PV-INs
Basal tonic GABA current
n Ihold control (pA) Ihold PTX (pA) RMS control (pA) RMS PTX (pA)
DGGC 5 –68.4 
 9.7 –56.3 
 8.3 5.2 
 0.4 3.2 
 0.2
PVIN 4 –85.9 
 8.6 –51.1 
 9.8 7.6 
 0.8 5.0 
 0.8
NNC- and GABA-evoked current
n Ihold control (pA) Ihold NNC/GABA (pA) RMS control (pA) RMS NNC/GABA (pA)
DGGC 12 –67.2 
 3.9 –140.3 
 11.5 4.6 
 0.1 12.6 
 0.8
PVIN 11 –147.8 
 20.8 193.4 
 21.1 8.1 
 0.7 11.7 
 0.7
Tonic GABA current in NNC and GABA
n Ihold NNC/GABA (pA) Ihold PTX (pA) RMS NNC/GABA (pA) RMS PTX (pA)
DGGC 6 –155.7 
 20.7 –59.2 
 6.9 13.2 
 1.5 3.6 
 0.8
PVIN 4 –148.6 
 23.6 –54.5 
 14.8 14.2 
 1.0 6.1 
 0.2
Zolpidem-evoked current
n Ihold NNC/GABA (pA) Ihold ZOLP (pA) RMS NNC/GABA (pA) RMS ZOLP (pA)
DGGC 6 –118.0 
 8.9 –113.7 
 7.1 11.8 
 0.7 11.0 
 0.7
PVIN 7 –205.6 
 30.2 –229.4 
 28.6 10.2 
 0.4 11.8 
 0.7
n  number of neurons from a minimum of three mice per genotype. p  0.05, p  0.01, p  0.001, p  0.0001.
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Figure 6. Tonic inhibition in PV-INs is sensitive to extracellular GABA concentration and modulated by the 1-selective ligand zolpidem.
A, Example traces showing the 3-fold larger basal tonic GABA current in PV-INs compared to DGGCs revealed by application of the
GABAA antagonist PTX. B, Example traces showing the modulation of tonic inhibition in PV
-INs and DGGCs by the elevation of
extracellular GABA concentration using NNC711 (10 M) and GABA (5 M). C, Example traces showing the modulation of tonic inhibition
in PV-INs, but not DGGCs, by the 1-selective ligand zolpidem. D, Scatter plots summarizing the changes in holding current (Ihold) in
DGGCs and PV-INs reflecting the basal tonic GABAergic inhibition, the current induced by NNC/GABA, the tonic GABA current in
NNC/GABA and the current induced by zolpidem. E, As in D for normalized currents (pA/pF). F, As in D for changes in RMS noise.
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cantly increase risk of development of neuropsychiatric
and neurodevelopmental disorders including schizophre-
nia, autism spectrum disorder and intellectual disability. In
this study, we set out to test the hypothesis that loss of a
single copy of the gene encoding the FMRP-interacting
protein Cyfip1, in a mouse model that mimics human
disorders, would result in disruption of GABAergic inhibi-
tion in the hippocampus. We focused in particular on tonic
GABAergic inhibition because disruption of this form of
inhibition, resulting from reduced expression of the
eGABAAR specific -subunit, has been previously dem-
onstrated following loss of FMRP in a model of FXS, the
Fmr1 KO mouse (D’Hulst et al., 2006; Curia et al., 2009;
Zhang et al., 2017). Contrary to our original hypothesis,
however, and in contrast to findings from the FXS mouse,
the results of our electrophysiological and histologic ex-
periments demonstrate that, in DGGC and GCL PV-INs,
loss of a single copy of the Cyfip1 gene is not sufficient to
produce changes in either phasic or tonic GABAergic
inhibition. However, we cannot rule out impaired GABAe-
rgic signaling in other subfields of the hippocampus (see
later), or other brain regions, in this genetic model.
In this study, we investigated GABAergic inhibition in
the DG of adolescent and adult WT and Cyfip1/– mice.
While the age of the adolescent mice (five to seven weeks)
used in the majority of our experiments broadly matches
the age of onset of schizophrenia symptoms in humans
(Jones, 2013) it is noteworthy that the underlying patho-
logic causes of schizophrenia are neurodevelopmental
and precede the presentation of symptoms, and diagno-
sis, by many years. Moreover, Cyfip1 is a risk factor for
both ASD and ID which are typically diagnosed in humans
at a much younger juvenile age (Jones et al., 2014). While
we did not investigate GABAergic inhibition earlier in post-
natal development, our results show a lack of functional
change in GABAergic inhibition in Cyfip1 haploinsufficient
adolescent mice that is in marked contrast to the effects
seen in juvenile (Olmos-Serrano et al., 2011; Sabanov
et al., 2017), adolescent/young adult (Curia et al., 2009)
and adult (Centonze et al., 2008) mice with the complete
loss of Fmr1. Our original hypothesis was that the con-
vergent function of Cyfip1 and Fmr1, through direct
Cyfip1-FMRP interaction (Napoli et al., 2008), would reg-
ulate the translation of GABAAR signaling components
(D’Hulst et al., 2006) and therefore influence inhibitory
GABAergic function (Sabanov et al., 2017). Clearly, based
on our new findings, this is not the case in the DG. Further,
the disparate phenotypes observed in GABAergic inhibi-
tion in Cyfip1 and Fmr1 KO animal models of genetic
psychiatric risk may simply relate to differing gene dosage
(single copy loss of Cyfip1 vs complete loss of Fmr1) and
the subsequent levels of severity this has on the stoichi-
ometry and/or function of the critically involved Cyfip1-
Fmr1 complex. Thus, our findings suggest that either the
interaction of CYFIP1 with FMRP is not critical in the
ability of the latter to regulate eGABAAR expression or that
a single copy of Cyfip1 is sufficient to allow high enough
protein expression to permit normal FMRP function. In the
context of human pathology, this is of critical significance
since CNVs at the 15q11.2 locus never result in CYFIP1
homozygosity and in mice, Cyfip1 homozygosity is em-
bryonically lethal. Thus, we conclude that disrupted tonic
GABAergic inhibition in the DG is unlikely to be a major
contributor to the pathology of 15q11.2 CNV related dis-
orders.
It should be noted that FMRP target mRNAs are
thought to consist of 842 mRNAs that bind to FMRP, as
part of a FMRP messenger ribonucleoprotein (mRNP)
complex, in the mouse forebrain (Darnell et al., 2011).
However, three separate studies have each found diverse
FMRP target datasets that only partially overlap with Dar-
nell’s FMRP mRNA targets (Brown et al., 2001; Miyashiro
et al., 2003; Ascano et al., 2012). FMRP, in concert with
CYFIP and as part of the functional FMRP-CYFIP1-eIF4E
complex, represses protein translation of some of the
FMRP target mRNAs (Napoli et al., 2008; Panja et al.,
2014; Santini et al., 2017). Furthermore, Cyfip1 and FMRP
proteins are known to form other neurobiological com-
plexes and therefore partake in a range of distinctive
functions. For instance, Cyfip1 forms part of the WAVE
complex to regulate cytoskeletal dynamics (Schenck
et al., 2001), and FMRP is a key hub protein, involved in
chromatin and ion channel binding, for instance (Davis
and Broadie, 2017), and so it might not be necessarily
expected that phenotypes (including GABAergic signal-
ing) of both models might closely map onto each other.
A critical feature of the DG is that it is one of only a few
brain regions where new neurons are generated during
adulthood. This process of neurogenesis, during which
new DGGC are produced, takes place in the SGZ and
GCL and is heavily modulated by GABAergic inhibition
(Aimone et al., 2014). In particular, PV-INs play an im-
portant role in the control of cellular proliferation and
migration by release of GABA onto both neural progenitor
cells (NPCs) and their progeny, new born DGGCs (Aimone
et al., 2014; Song et al., 2012). It is therefore possible that
more subtle or specific effects of the loss of Cyfip1 may
have a disruptive effect on GABAergic modulation of
NPCs or immature DGGCs and thus impact on the neu-
rogenic process although this remains to be investigated.
Moreover, tonic inhibition mediated by -subunit-
containing eGABAAR is not restricted to the DG of the
hippocampus but plays a critical role in controlling cellular
excitability in other hippocampal subfields and brain re-
gions including the thalamus, cortex, cerebellum and
striatum. In fact, Davenport and colleagues (2019) have
recently examined the effect of complete Cyfip1 knock-
out and GABA signaling in the CA1. Forebrain-specific
Cyfip1 knock-out mice were shown to have increased
mIPSCs in CA1 pyramidal cells, with an overall change in
excitatory and inhibitory (E/I) balance. Intriguingly, the
opposite effect was shown when Cyfip1 was overex-
pressed in cultured hippocampal neurons with decreased
mIPSC amplitude, increased mEPSC frequency and an
overall increase in E/I balance. Differences between our
findings and those of Kittler might genuinely reflect pleio-
tropic effects of reduced Cyfip1 dosage across different
hippocampal subfields (DG vs CA1). It should also be
noted that Kittler’s findings derive from both the complete
loss and in vitro overexpression of Cyfip1, while our data
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derives from the constitutive Cyfip1 haploinsufficient
mouse, modeling a CNV deletion that confers increased
risk to a range of psychiatric disorders.
Tonic inhibition in GCL PV-INs
We found a lack of any genotype dependent functional
difference in GABAergic signaling between WT and Cy-
fip1/– mice in GCL PV-INs. Our results do not rule out
the possibility of genotype dependent differences in the
expression of GABAAR subunits specifically in PV
-INs
but do strongly suggest that any potential differences do
not translate to deficits in functional inhibition in Cyfip1
haploinsufficient mice. Future studies, perhaps using
single-cell RT-PCR or RNAseq techniques may provide
further insight into the exact GABAAR subunit make-up in
these cells following disruption of Cyfip1. However, de-
spite the lack of functional effects of Cyfip1 on tonic
GABAergic inhibition in GCL PV-INs, our experiments
have demonstrated, for the first time to our knowledge,
that (1) PV-INs in the GCL express functional eGABAAR,
(2) that these receptors incorporate -subunits, and that
(3) at least a proportion of the tonic inhibition in these cells
is likely to be mediated through eGABAAR containing
1-subunits. Several lines of evidence lead us to these
conclusions. In GCL PV-INs, we found that the increase
in tonic GABA current, when the concentration of extra-
cellular GABA was raised by adding GABA to the bath
along with the GAT-1 blocker NNC711, was less than that
observed in DGGCs. Previously, Milenkovic et al. (2013)
found ubiquitous expression GABAAR -subunits, high 1
and low 4 GABAAR subunit expression and strong co-
localization of 1-, 2-, and -subunits in GCL PV
-INs.
This data strongly suggested that these interneurons ex-
press 1/ eGABAAR as has been described previously for
interneurons of the ML of the DG (Glykys et al., 2007). In
the Xenopus oocyte expression system, it has been
shown that 13 GABAAR have a markedly lower affinity
for GABA [EC50: 8.7 M (Karim et al., 2012); EC50: 8.5 M
(Kaur et al., 2009)] than 42 containing GABAAR [EC50:
1 M (Karim et al., 2012); EC50: 0.41 M (Wongsamitkul
et al., 2017)] but that both of these -subunit containing
GABAAR display properties of constitutive activity (Karim
et al., 2012). This latter finding has been confirmed in rat
DGGC where tonic currents at resting extracellular GABA
levels appear to be largely mediated by -subunit con-
taining GABAAR displaying GABA-independent channel
openings (Wlodarczyk et al., 2013). Moreover, in mamma-
lian expression systems, when GABA is used as the ag-
onist, 13 and 42 GABAAR have been shown to have
similar single channel conductances (Fisher and MacDon-
ald, 1997; Keramidas and Harrison, 2008) and in DGGC
expressing 42 receptors GABA-independent single
channel currents are equivalent size to those in the pres-
ence of GABA (Wlodarczyk et al., 2013). Thus, based on
our finding of similar normalized basal tonic currents in
DGGCs (1.4 
 0.4 pA/pF) and PV-INs (1.2 
 0.1 pA/pF)
and the previously reported similarities in 4/ and 1/
receptor single channel conductances, we suggest that
these cells express roughly similar densities of 4 and 1
containing eGABAAR, respectively. We propose that at
resting extracellular GABA levels, tonic currents in both
DGGCs and PV-INs are mediated by constitutive activity
relying largely on GABA independent channel openings.
This conclusion stems from the fact that the ambient level
of extracellular GABA in the DG has been shown to be
sufficiently low to indicate that the majority of tonic inhi-
bition in DGGCs, which is mediated by higher affinity
42, is via GABA-independent channel openings (Wlo-
darczyk et al., 2013). Thus, at low basal ambient GABA
levels, where a reasonably large tonic current is observed
in PV-INs, it is unlikely that lower affinity 1X eGABAAR
would be strongly activated by the neurotransmitter while
higher affinity 42 receptors in DGGC are not. However,
as the extracellular GABA concentration is elevated, the
differential expression of eGABAAR with substantially dif-
ferent GABA affinities (42 		 1X) between the two
type of cells means that tonic currents are more strongly
enhanced in DGGCs compared to PV-INs (i.e., the con-
centration response curve for GABA is significantly left-
shifted in DGGCs vs PV-INs). It is unclear precisely what
the physiologic function of this difference in eGABAAR
composition is. One possibility is that lower sensitivity to
GABA in fast-spiking PV-INs might permit these cells to
elevate the level of extracellular GABA in the GCL, via
perisomatic release of GABA, to a point where it can
effectively enhance tonic inhibition to DGGCs and reduce
their firing without producing substantial tonic inhibitory
feedback onto themselves or other PV-INs that are in
close physical proximity in the GCL. This could allow
PV-INs to respond to strong excitation by providing
substantial feedforward inhibition to DGGCs. On the other
hand, PV-INs in the GCL have dense axonal projections
in the GCL itself and are typically perisoma-inhibiting cells
(Hu et al., 2014). Whereas, the expression of 4- and
-subunits, and therefore 42 eGABAAR, in DGGCs is
greatest in their dendrites in the ML, the strongest expres-
sion of 1- and -subunits in GCL PV
-INs is at the soma
(Milenkovic et al., 2013). Thus, by expressing lower affinity
somatic eGABAAR, when PV
-INs fire strongly, as hap-
pens for example during -oscillations, they can provide
robust temporally precise synaptic inhibition to the soma
of nearby DGGCs (Strüber et al., 2015, 2017), without the
resulting GABA spill-over impacting substantially on their
own firing allowing them to maintain precise control of the
timing of DGGC firing. Nonetheless, the presence of
eGABAAR, albeit lower affinity ones, in GCL PV
-INs
would still provide a valuable auto-inhibitory backstop to
regulate their own output should the extracellular GABA
concentration become sufficiently elevated.
Our new findings reveal that tonic inhibition in GCL
PV-INs, unlike DGGCs, is sensitive to the 1-selective
drug zolpidem. Thus, it is highly likely that at least a
fraction of the tonic inhibition in PV-INs, unlike DGGCs,
is mediated by receptors containing 1-subunits, possibly
in arrangements containing -subunits or as  pentam-
ers. Although it is conventionally thought that zolpidem
binding requires the presence of -subunits that are not
commonly found in eGABAARs, recent evidence has dem-
onstrated a novel binding site for zolpidem at the interface
between two 1-subunits (Che Has et al., 2016), further
Negative Results 17 of 20
May/June 2019, 6(3) ENEURO.0364-18.2019 eNeuro.org
supporting the existence of 1X eGABAAR. Thus, PV
-
INs may express distinct populations of eGABAAR with
unique pharmacological properties that would allow them
to be targets for new subunit-selective GABA modulating
drugs. These receptors might represent novel targets for
treatment of neurodevelopmental and neuropsychiatric
disorders where PV-INs have long been implicated in
disease (Lewis et al., 2012; Nakazawa et al., 2012).
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